Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.65B P/E - EPS this Y -62.20% Ern Qtrly Grth -
Income -173.58M Forward P/E -17.85 EPS next Y -21.90% 50D Avg Chg 8.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 38.00%
Dividend N/A Price/Book 5.96 EPS next 5Y - 52W High Chg -8.00%
Recommedations 1.50 Quick Ratio 17.23 Shares Outstanding 65.11M 52W Low Chg 225.00%
Insider Own 2.89% ROA -22.71% Shares Float 35.55M Beta 1.28
Inst Own 103.32% ROE -32.81% Shares Shorted/Prior 6.41M/6.83M Price 46.59
Gross Margin - Profit Margin - Avg. Volume 294,537 Target Price 112.40
Oper. Margin - Earnings Date - Volume 216,336 Change -5.00%
About Nuvalent, Inc.

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Nuvalent, Inc. News
11/12/24 Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
09/19/24 Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
09/18/24 Nuvalent Announces Closing of Upsized Public Offering of Common Stock
09/18/24 Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
09/17/24 Company News for Sep 17, 2024
09/16/24 Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
09/16/24 Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
09/16/24 Cancer Biotech Nuvalent’s Stock Jumps on Positive Data
09/16/24 Nuvalent Announces Public Offering of Common Stock
09/14/24 Nuvalent, Inc. (NUVL): Among Hedge Funds’ Top Biotech Stock Picks
09/14/24 Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock
09/14/24 Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
09/13/24 Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
09/09/24 Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles
08/29/24 Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
08/29/24 Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
08/08/24 Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results
07/23/24 Nuvalent doses first subject in Phase Ia/Ib trial of lung cancer treatment
07/22/24 Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
07/16/24 Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
NUVL Chatroom

User Image IN0V8 Posted - 1 week ago

$NUVL Opportunity BMO raises target price to $134 from $132 Jefferies raises target price to $137 from $97 Stifel cuts target price to $132 from $135

User Image IN0V8 Posted - 1 week ago

$NUVL Opportunity BMO raises target price to $134 from $132 Jefferies raises target price to $137 from $97

User Image RoyMunson69 Posted - 2 weeks ago

$NUVL I'm dying of boredom on this one but have to wait for long term gains

User Image SeanWav Posted - 10/30/24

$NUVL $NVCT great NXP800 data.

User Image SeanWav Posted - 10/30/24

$NVCT $NUVL

User Image SeanWav Posted - 10/30/24

$NUVL $NVCT great data to cure deadly diseases.

User Image SeanWav Posted - 10/30/24

@BioSensai This should be the next $NUVL $200++ in the next 6-12 months

User Image insiderbuyingselling Posted - 10/30/24

$NUVL new insider selling: 2000 shares. http://insiderbuyingselling.com/?t=NUVL

User Image SeanWav Posted - 10/25/24

$NVCT Precision medicine targeting unmet needs in oncology founder owned and led with 2/3 float insider owned pre. Founders have a flawless track record of success. $150mm market cap with comparable companies like $SMMT and $nuvl that have 10-50x $nvct market cap transformative data for NXP-800 on 15 patients out NEXT WEEK. Expect $50+ on this with efficacy of over 30%. SOC has less than 5% efficacy :-( NXP-900 safety data out in November-December. This is also a MAJOR catalyst, as issue with existing drug is safety at required effective doses. Precision medicine FTW! $200-$400+ by this time next year with both drugs. Both orphan drug and fast track. Both approved after phase 2a as unmet need in oncology 5mm shares open float. 1mm shares shorted. Going to absolutely move HIIIIGH with data release.

User Image WangSLO Posted - 10/25/24

$NUVL puts are so expensive

User Image insiderbuyingselling Posted - 10/24/24

$NUVL new insider selling: 2000000 shares. http://insiderbuyingselling.com/?t=NUVL

User Image hope_my_calls_print Posted - 10/23/24

$NUVL still a good hold for long term, will look to add to position if we drop down to 80ish

User Image IN0V8 Posted - 10/23/24

$NUVL Bought at $96.50

User Image BioSensai Posted - 1 month ago

$NVCT and here we are sitting at $150mm with drugs that are both addressing what $imgn and $nuvl had!!!! $imgn = NXP-800 $nuvl = NXP-900

User Image BioSensai Posted - 1 month ago

$NVCT Folks this is a $50+ MINIMUM stock after NXP-800 data. Comps are $imgn which sold for $10B after phase 2b and $nuvl which valued at $7b after 1b data

User Image Doozio Posted - 1 month ago

$NUVL 3wt wit da huckleberries thru da $$$$$ during 🧠⏰♾️

User Image insiderbuyingselling Posted - 1 month ago

$NUVL new insider selling: 27000 shares. http://insiderbuyingselling.com/?t=NUVL

User Image Grouphome Posted - 1 month ago

$NUVL little extended but thats a nice look

User Image IN0V8 Posted - 1 month ago

$NUVL JP Morgan raises target price to $125 from $100

User Image vjtweet Posted - 1 month ago

$NUVL acting well at a nice round number after a controlled pullback. At a good entry point here.

User Image insiderbuyingselling Posted - 09/25/24

$NUVL new insider selling: 2000 shares. http://insiderbuyingselling.com/?t=NUVL

User Image waugusti Posted - 09/24/24

$BDTX Is $bdtx the next $nuvl ? $nuvl leads in nextgen Inhibitors for ROS1 and ALK. $bdtx leads in nextgen TKI for EGFRm.

User Image kshonstocks Posted - 09/23/24

$NUVL dippers showing

User Image kshonstocks Posted - 09/23/24

$NUVL rinse is on MUCH lower volume i love these plays

User Image kshonstocks Posted - 09/23/24

taking some $NUVL here on the lower volume pullback

User Image howardlindzon Posted - 2 months ago

$NUVL great trend with no friend in biotech

User Image BixbyKnolls Posted - 2 months ago

$IBRX Market will come to this. Anktiva is the real game changer in cancer. Yeah, plenty of happenings. $SMMT $NUVL . we just got a blockbuster new cancer drug with a big market just FDA approved. 🚀

User Image kshonstocks Posted - 2 months ago

$NUVL holding pricing well 96 B+ ibd https://research.investors.com/stock-quotes/nasdaq-nuvalent-nuvl.htm

User Image TechnicalAbe47 Posted - 2 months ago

$RYTM just like $NUVL, i bought it just based on technicals, i don’t even know how to pronounce their name, just make me money that is all i want.

User Image Fullratio Posted - 2 months ago

$NUVL debt is 100% smaller than its equity: https://fullratio.com/stocks/nasdaq-nuvl/nuvalent

Analyst Ratings
Guggenheim Buy Sep 16, 24
Wedbush Outperform Sep 16, 24
BMO Capital Outperform Sep 16, 24
Stifel Buy Sep 16, 24
Wedbush Outperform Sep 9, 24
JP Morgan Overweight Sep 4, 24
Barclays Overweight Aug 29, 24
Stifel Buy Jul 10, 24
Wedbush Outperform May 17, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Shair Matthew Director Director Dec 26 Sell 75.17 119,150 8,956,506 1,724,698 12/28/23
Protopapas Anna Director Director Dec 18 Sell 75.67 5,000 378,350 12/20/23
Protopapas Anna Director Director Dec 18 Option 9.36 5,000 46,800 5,000 12/20/23
Noci Darlene Chief Development Of.. Chief Development Officer Dec 18 Sell 75.82 40,000 3,032,800 12/20/23
Noci Darlene Chief Development Of.. Chief Development Officer Dec 18 Option 7.46 40,000 298,400 40,000 12/20/23
Miller Deborah Ann Chief Legal Officer Chief Legal Officer Dec 18 Sell 75.41 38,046 2,869,049 12/20/23
Miller Deborah Ann Chief Legal Officer Chief Legal Officer Dec 18 Option 23.39 38,046 889,896 5,000 12/20/23
Balcom Alexandra Chief Financial Offi.. Chief Financial Officer Dec 18 Option 1.08 30,000 32,400 30,000 12/20/23
Balcom Alexandra Chief Financial Offi.. Chief Financial Officer Dec 18 Sell 75.82 30,000 2,274,600 12/20/23
Shair Matthew Director Director Nov 28 Sell 62.03 9,150 567,574 1,843,848 11/30/23
Shair Matthew Director Director Oct 24 Sell 50.93 91,700 4,670,281 1,852,998 10/26/23
Turner Christopher Durant Chief Medical Office.. Chief Medical Officer Oct 04 Sell 55.01 7,995 439,805 14,513 10/06/23
Turner Christopher Durant Chief Medical Office.. Chief Medical Officer Oct 04 Option 6.89 7,995 55,086 22,508 10/06/23
Noci Darlene Chief Development Of.. Chief Development Officer Oct 04 Sell 56.48 20,000 1,129,600 10/06/23
Noci Darlene Chief Development Of.. Chief Development Officer Oct 04 Option 3.99 20,000 79,800 20,000 10/06/23
Noci Darlene Chief Development Of.. Chief Development Officer Aug 01 Sell 49.88 3,000 149,640 08/01/23
Noci Darlene Chief Development Of.. Chief Development Officer Aug 01 Option 1.08 3,000 3,240 3,000 08/01/23
Turner Christopher Durant Chief Medical Office.. Chief Medical Officer Jul 26 Option 6.89 5,030 34,657 17,178 07/28/23
Turner Christopher Durant Chief Medical Office.. Chief Medical Officer Jul 26 Sell 47.89 5,030 240,887 14,513 07/28/23
Turner Christopher Durant Chief Medical Office.. Chief Medical Officer Jul 20 Sell 46.81 300 14,043 14,513 07/24/23
Turner Christopher Durant Chief Medical Office.. Chief Medical Officer Jul 20 Option 6.89 300 2,067 14,713 07/24/23
Noci Darlene Chief Development Of.. Chief Development Officer Jul 03 Sell 41.73 3,000 125,190 07/06/23
Noci Darlene Chief Development Of.. Chief Development Officer Jul 03 Option 1.08 3,000 3,240 3,000 07/06/23
Miller Deborah Ann Chief Legal Officer Chief Legal Officer May 05 Sell 39.64 4,132 163,792 05/09/23
Miller Deborah Ann Chief Legal Officer Chief Legal Officer May 05 Option 6.89 4,132 28,469 1,332 05/09/23
Miller Deborah Ann Chief Legal Officer Chief Legal Officer Apr 17 Sell 29.74 2,000 59,480 04/19/23
Miller Deborah Ann Chief Legal Officer Chief Legal Officer Apr 17 Option 6.89 2,000 13,780 2,000 04/19/23
Noci Darlene Chief Development Of.. Chief Development Officer Aug 15 Option 1.08 2,596 2,804 2,596 08/17/22
Noci Darlene Chief Development Of.. Chief Development Officer Aug 15 Sell 17.02 2,596 44,184 08/17/22
Noci Darlene Chief Development Of.. Chief Development Officer Jul 15 Option 1.08 4,200 4,536 318 07/19/22
Noci Darlene Chief Development Of.. Chief Development Officer Jul 15 Sell 17.37 4,200 72,954 07/19/22
Shair Matthew Director Director Jul 13 Sell 18.27 2,100 38,367 2,162,598 07/15/22
Noci Darlene See Remarks See Remarks Jul 07 Option 1.08 16,800 18,144 16,800 07/08/22
Noci Darlene See Remarks See Remarks Jul 07 Sell 17.61 16,800 295,848 07/08/22
Noci Darlene See Remarks See Remarks Feb 15 Option 1.08 4,200 4,536 4,200 02/16/22
Noci Darlene See Remarks See Remarks Feb 15 Sell 17.17 4,200 72,114 02/16/22